Passkey Therapeutics is at the forefront of developing Synergistic Multifunctional Therapeutics (SMThs), a novel class of drugs designed to target rare combinations of proteins, referred to as Multilogs. Traditional drug development typically focuses on monofunctional drugs that target a single protein, which can limit their effectiveness due to the complex interplay of multiple proteins in biological systems. By identifying and targeting Multilogs, Passkey aims to address two significant biological complexities: redundancy and compensation. This approach allows for a more comprehensive treatment strategy, as targeting multiple proteins simultaneously can enhance therapeutic efficacy in complex diseases, such as cancer, autoimmune disorders, and neurodegenerative conditions.

The company utilizes its proprietary Locksmith platform, which combines advanced computational and experimental techniques to analyze human genetic data and discover Multilogs. This platform enables the rapid identification and validation of these protein combinations, facilitating the design of SMThs that can take various forms, including small molecules and biologics like antibodies. By leveraging the inherent complexity of disease biology, Passkey Therapeutics is positioned to create innovative therapies that can significantly improve treatment outcomes for patients facing challenging health conditions.

United States

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics or SMThs, designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions.

Passkey Therapeutics

Company Details